Richard S B Wanless1, Sorin Rugină2, Simona Maria Ruţă3, Irina-Magdalena Dumitru2, Roxana Carmen Cernat4, Heidi L Schwarzwald5, Nancy R Calles6, Gordon E Schutze5, Ana-Maria Schweitzer7, Heather R Draper8, Mark W Kline9. 1. MB, ChB, PhD, Baylor College of Medicine International Pediatric AIDS Initiative, Texas Children's Hospital, Houston, Texas, USA. 2. MD, PhD, Ovidius University of Constanţa; Clinical Hospital of Infectious Diseases, Constanţa, Romania. 3. MD, PhD, Carol Davila University of Medicine and Pharmacy, Bucharest; Ştefan S. Nicolau Institute of Virology, Bucharest, Romania. 4. MD, Clinical Hospital of Infectious Diseases, Constanţa, Romania. 5. MD, Baylor College of Medicine, Houston, Texas, USA. 6. RN, MSN, MPH, Baylor College of Medicine International Pediatric AIDS Initiative, Houston, Texas, USA. 7. MA, Baylor-Black Sea Foundation, Constanţa, Romania. 8. MS Baylor College of Medicine International Pediatric AIDS Initiative, Texas Children's Hospital, Houston, Texas, USA. 9. MD Baylor College of Medicine International Pediatric AIDS Initiative, Texas Children's Hospital, Houston, Texas, USA.
Abstract
INTRODUCTION: Many Romanian children were infected nosocomially with human immunodeficiency virus (HIV) in the late 1980s. The Romanian-American Children's Center of Excellence in Constanţa continues to follow approximately 450 of these patients. In 2001, 414 of these patients were initiated on triple therapy including lopinavir/ritonavir. Data from this cohort treated through August 2006 were published in April 2007 demonstrating that the treatment was well tolerated, with 337 children (81%) remaining on therapy after a median duration of >4 years. The current article describes the results of continued analysis of this cohort through end 2010. The objective of the study was to determine the long-term clinical outcomes of children and adolescents commenced on antiretroviral therapy (ART) including lopinavir/ritonavir. METHODS: Data were extracted retrospectively from the charts of the 336 patients remaining on lopinavir/ritonavir in August 2006. The following outcomes were analyzed: mortality, current patient status, viral load (VL), CD4 counts and reasons for discontinuation of lopinavir/ritonavir. RESULTS: The median age at initiation of lopinavir/ritonavir was 14.0 years (range 5.4 to 20.0 years). The median time on lopinavir/ritonavir treatment was 7.5 years (interquartile range 5.7 to 8.6 years). Overall mortality was 13.5%. Of the original 414 patients started on lopinavir/ritonavir in 2001, 199 (48.1%) remained on this therapy at the end of 2010 and of these 63.8% had undetectable viral load. CONCLUSION: Despite initial suboptimal ART, a significant proportion of patients subsequently treated with a lopinavir/ritonavir based regimen remained on this therapy for up to nine years.
INTRODUCTION: Many Romanian children were infected nosocomially with human immunodeficiency virus (HIV) in the late 1980s. The Romanian-American Children's Center of Excellence in Constanţa continues to follow approximately 450 of these patients. In 2001, 414 of these patients were initiated on triple therapy including lopinavir/ritonavir. Data from this cohort treated through August 2006 were published in April 2007 demonstrating that the treatment was well tolerated, with 337 children (81%) remaining on therapy after a median duration of >4 years. The current article describes the results of continued analysis of this cohort through end 2010. The objective of the study was to determine the long-term clinical outcomes of children and adolescents commenced on antiretroviral therapy (ART) including lopinavir/ritonavir. METHODS: Data were extracted retrospectively from the charts of the 336 patients remaining on lopinavir/ritonavir in August 2006. The following outcomes were analyzed: mortality, current patient status, viral load (VL), CD4 counts and reasons for discontinuation of lopinavir/ritonavir. RESULTS: The median age at initiation of lopinavir/ritonavir was 14.0 years (range 5.4 to 20.0 years). The median time on lopinavir/ritonavir treatment was 7.5 years (interquartile range 5.7 to 8.6 years). Overall mortality was 13.5%. Of the original 414 patients started on lopinavir/ritonavir in 2001, 199 (48.1%) remained on this therapy at the end of 2010 and of these 63.8% had undetectable viral load. CONCLUSION: Despite initial suboptimal ART, a significant proportion of patients subsequently treated with a lopinavir/ritonavir based regimen remained on this therapy for up to nine years.
Authors: H Knobel; A Guelar; A Carmona; M Espona; A González; J L López-Colomés; P Saballs; J L Gimeno; A Díez Journal: AIDS Patient Care STDS Date: 2001-04 Impact factor: 5.078
Authors: Mary-Ann Davies; Harry Moultrie; Brian Eley; Helena Rabie; Gilles Van Cutsem; Janet Giddy; Robin Wood; Karl Technau; Olivia Keiser; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Sandra De Meyer; Erkki Lathouwers; Inge Dierynck; Els De Paepe; Ben Van Baelen; Tony Vangeneugden; Sabrina Spinosa-Guzman; Eric Lefebvre; Gaston Picchio; Marie-Pierre de Béthune Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Xavier Sáez-Llorens; Avyi Violari; Carl O Deetz; Richard A Rode; Perry Gomez; Edward Handelsman; Stephen Pelton; Octavio Ramilo; Pedro Cahn; Ellen Chadwick; Upton Allen; Stephen Arpadi; Maria Mercedes Castrejón; Renee S Heuser; Dale J Kempf; Richard J Bertz; Ann F Hsu; Barry Bernstein; Cheryl L Renz; Eugene Sun Journal: Pediatr Infect Dis J Date: 2003-03 Impact factor: 2.129
Authors: Mark W Kline; Rodica F Matusa; Letitia Copaciu; Nancy R Calles; Nancy E Kline; Heidi L Schwarzwald Journal: Pediatr Infect Dis J Date: 2004-08 Impact factor: 2.129